Abstract: The present invention relates to methods for enhancing, extending and accelerating the cosmetic benefits certain non-surgical dermal interventions, examples of which include treatment with aesthetic injectables such as botulinum toxin and dermal fillers, as well as intense pulsed light (IPL) treatments, particularly cosmetic treatments characterized by the injection of botulinum toxin compositions, such as Botox® and Dysport®, and/or dermal fillers, such as Restylane® and Juviderm®. More particularly, the present invention relates to the unexpected discovery that the combination of micron-sized particulate bioactive glass and medical grade hyaluronic acid yields a cosmetic composition that is capable of improving and prolonging the anti-wrinkle effects of such cosmetic therapies as well as to afford enhanced and improved healing and anti-microbial benefits at the site(s) of injection.

Abstract: The present invention relates to methods for enhancing, extending and accelerating the cosmetic benefits certain non-surgical dermal interventions, examples of which include treatment with aesthetic injectables such as botulinum toxin and dermal fillers, as well as intense pulsed light (IPL) treatments, particularly cosmetic treatments characterized by the injection of botulinum toxin compositions, such as Botox® and Dysport®, and/or dermal fillers, such as Restylane® and Juviderm®. More particularly, the present invention relates to the unexpected discovery that the combination of micron-sized particulate bioactive glass and medical grade hyaluronic acid yields a cosmetic composition that is capable of improving and prolonging the anti-wrinkle effects of such cosmetic therapies as well as to afford enhanced and improved healing and anti-microbial benefits at the site(s) of injection.

Abstract: An implantable article for cartilage repair by implantation in an animal. The implantable article includes a support matrix, and chondrocyte cells and a bio-compatible adhesive adhered to an edge of the support matrix, wherein the support matrix is absorbable by the animal. The support matrix is a biocompatible material such as collagen, and the adhesive is autologous fibrin.

Abstract: An implantable article for cartilage repair by implantation in an animal. The implantable article includes a support matrix, and chondrocyte cells and a bio-compatible adhesive adhered to an edge of the support matrix, wherein the support matrix is absorbable by the animal. The support matrix is a biocompatible material such as collagen, and the adhesive is autologous fibrin.

Abstract: A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.

Abstract: A composition including one or more growth factors suitable for the treatment of osteogenesis, tenogenesis, or chondrogenesis, wherein the growth factors are obtained from cultured chondrocytes.

Abstract: An implantable article for cartilage repair by implantation in an animal. The implantable article includes a support matrix, and chondrocyte cells and a bio-compatible adhesive adhered to an edge of the support matrix, wherein the support matrix is absorbable by the animal. The support matrix is a biocompatible material such as collagen, and the adhesive is autologous fibrin.

Abstract: This invention relates to the oral administration of forms of hyaluronic acid (for example hyaluronan (hyaluronic acid) and pharmaceutically acceptable salts thereof such as sodium hyaluronate), and orally administrable dosage forms containing forms of hyalruonic acid, for the prevention and/or treatment of diseases and/or conditions such as the prevention of restenosis and the treatment of an infarct (heart attack) or a stroke. The oral administration and the orally administered dosage forms may also include therapeutic agents and/or medicines which may be administered orally for the treatment and/or prevention of the diseases and/or conditions with the forms of hyaluronic acid (hyaluronan) previously described.

Abstract: A method of treating a human suffering a disease or condition caused by a gene, cDNA or RNA-DNA oligonucleotide or RNA-DNA oligonucleotide hybrids or messenger RNA implicated in a disease or condition involving cells that express hyaluronic acid receptors is provided, the method comprising administering to such human, an effective dosage amount of a pharmaceutical composition comprising an effective amount of a form of hyaluronic acid selected from hyaluronic acid and/or a pharmaceutically acceptable salt thereof associated with/bound with an effective amount of anti-sense to the gene, cDNA or RNA-DNA oligonucleotide or RNA-DNA oligonucleotide hybrids or messenger RNA implicated in the disease or condition in a suitable pharmaceutically acceptable diluent.

Abstract: The present invention describes various support matrices to which cells can adhere and proliferate. Such support matrices are useful for implantation in a wound site to promote healing and regeneration of damaged tissue. The present invention further describes an article including a membrane having at least one layer having a porous surface and also including submucosal intestine tissue, and cells adhered to the layer. The present invention further describes that the cells adhered to the layer include chondrocyte cells.

Abstract: An apparatus comprising a first frame and a second frame adjacent to the first frame, for storing, transporting, and maintaining a biomaterial. In one embodiment, an inner wall of the first frame lockingly engages an outer wall of the second frame. In another embodiment, the apparatus includes a container for holding the first frame and second frame.

Abstract: A method of treating a human suffering a disease or condition caused by a gene, cDNA or RNA-DNA oligonucleotide or RNA-DNA oligonucleotide hybrids or messenger RNA implicated in a disease or condition involving cells that express hyaluronic acid receptors is provided, the method comprising administering to such human, an effective dosage amount of a pharmaceutical composition comprising an effective amount of a form of hyaluronic acid selected from hyaluronic acid and/or a pharmaceutically acceptable salt thereof associated with/bound with an effective amount of anti-sense to the gene, cDNA or RNA-DNA oligonucleotide or RNA-DNA oligonucleotide hybrids or messenger RNA implicated in the disease or condition in a suitable pharmaceutically acceptable diluent.

Abstract: An implantable article for cartilage repair by implantation in an animal. The implantable article includes a support matrix, and chondrocyte cells and a bio-compatible adhesive adhered to an edge of the support matrix, wherein the support matrix is absorbable by the animal. The support matrix is a biocompatible material such as collagen, and the adhesive is autologous fibrin.

Abstract: A kit and a method for the effective treatment of articulating joint surface cartilage (10) by the transplantation of chondrocytes (18) to a surface to be treated. The method includes the steps of placing chondrocytes (18) in a defect (30) of the articulating joint surface, and covering the surface to be treated with an absorbable covering cap (16). The present invention also includes a kit for chondrocyte transplantation including a covering cap (16) and securing device.

Abstract: For the prevention of the narrowing of the tubular walls of an animal after the tubular walls have been traumatized, the administration of a therapeutically effective non-toxic amount of a form of Hyaluronic Acid selected from Hyaluronic Acid, salts thereof and combinations thereof to the animal to prevent narrowing of the tubular walls.

Abstract: A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.

Abstract: The use of an effective amount of a composition comprising an N.S.A.I.D. and a form of hyaluronic acid selected from hyaluronic acid, pharmaceutically acceptable salts thereof, fragments thereof and/or subunits thereof for mucous membrane trauma, disease, and/or pain relief.

Abstract: Pharmaceutical compositions from which effective non-toxic (to the patient) dosage amounts may be taken and applied to the skin and/or exposed tissue of a human, each effective dosage amount comprising pharmaceutical excipients suitable for topical application, an effective non-toxic dosage amount of a drug to treat and to assist to resolve a disease and/or condition of the skin and/or exposed tissue or a human and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units or hyaluronic acid sufficient to transport (to facilitate or cause the transport of) the drug, to a site in the skin including epidermis or exposed tissue or a disease or condition for percutaneous transport into the skin and/or exposed tissue to accumulate and remain there for a prolonged period of time and which is systemic independent acting.

Abstract: Pharmaceutical compositions from which effective non-toxic (to the patient) dosage amounts may be taken and applied to the skin and/or exposed tissue of a human, each effective dosage amount comprising pharmaceutical excipients suitable for topical application, an effective non-toxic dosage amount of a drug to treat and to assist to resolve a disease and/or condition of the skin and/or exposed tissue of a human and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid sufficient to transport (to facilitate or cause the transport of) the drug, to a site in the skin including epidermis or exposed tissue of a disease or condition for percutaneous transport into the skin and/or exposed tissue to accumulate and remain there for a prolonged period of time and which is systemic independent acting.

Abstract: A pharmaceutical composition is provided comprising:(1) an agent selected from a medicinal agent and a therapeutic agent and combinations thereof in a therapeutically effective amount to treat a disease or condition in humans who will benefit from the treatment with the agent; and(2) hyaluronic acid and/or pharmaceutically acceptable salts thereof and/or fragments, and subunits of hyaluronic acid, characterized in that said composition(a) is in a dosage form which is suitable for administration in humans; and(b) is in a form in which (i) component (1) is in an effective dosage amount to treat said disease or condition by penetration at the site to be treated; and (ii) component (2) is immediately available to transport component (1) at the site to be treated, and which component (2) is in an effective non-toxic amount to facilitate the transport of component (1) upon administration, through the tissue including scar tissue, at the site to be treated and through the cell membranes or the individual cells to be